Dataset Information

Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs.

ABSTRACT: Using the crystal structure of SARS-CoV-2 papain-like protease (PLpro) as a template, we developed a pharmacophore model of functional centers of the PLpro inhibitor-binding pocket. With this model, we conducted data mining of the conformational database of FDA-approved drugs. This search identified 147 compounds that can be potential inhibitors of SARS-CoV-2 PLpro. The conformations of these compounds underwent 3D fingerprint similarity clusterization, followed by docking of possible conformers to the binding pocket of PLpro. Docking of random compounds to the binding pocket of protease was also done for comparison. Free energies of the docking interaction for the selected compounds were lower than for random compounds. The drug list obtained includes inhibitors of HIV, hepatitis C, and cytomegalovirus (CMV), as well as a set of drugs that have demonstrated some activity in MERS, SARS-CoV, and SARS-CoV-2 therapy. We recommend testing of the selected compounds for treatment of COVID-19.

SUBMITTER: Kouznetsova VL

PROVIDER: S-EPMC7505060 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs.

Kouznetsova Valentina L VL Zhang Aidan A Tatineni Mahidhar M Miller Mark A MA Tsigelny Igor F IF

PeerJ 20200918

Using the crystal structure of SARS-CoV-2 papain-like protease (PLpro) as a template, we developed a pharmacophore model of functional centers of the PLpro inhibitor-binding pocket. With this model, we conducted data mining of the conformational database of FDA-approved drugs. This search identified 147 compounds that can be potential inhibitors of SARS-CoV-2 PLpro. The conformations of these compounds underwent 3D fingerprint similarity clusterization, followed ...[more]

PMID: 32999768

Dataset Information

Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs.

Publications

Potential COVID-19 papain-like protease PL<sup>pro</sup> inhibitors: repurposing FDA-approved drugs.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Similar Datasets

MERS-CoV papain-like protease (PL<sup>pro</sup>): expression, purification, and spectroscopic/thermodynamic characterization.
| S-EPMC5449288 | biostudies-literature

Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M<sup>pro</sup>.
| S-EPMC9057460 | biostudies-literature

SARS-CoV-2 M<sup>pro</sup> inhibitors: identification of anti-SARS-CoV-2 M<sup>pro</sup> compounds from FDA approved drugs.
| S-EPMC7651494 | biostudies-literature

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
| S-EPMC7194560 | biostudies-literature

Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease.
| S-EPMC8342870 | biostudies-literature

Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
| S-EPMC7332862 | biostudies-literature

Repurposing FDA-approved drugs for the treatment of malignant peripheral nerve sheath tumors
2023-10-21 | GSE159896 | GEO

Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
| S-EPMC8714248 | biostudies-literature

Metallodrug Profiling against SARS-CoV-2 Target Proteins Identifies Highly Potent Inhibitors of the S/ACE2 interaction and the Papain-like Protease PL<sup>pro</sup>.
| S-EPMC8653295 | biostudies-literature

Repurposing FDA-Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease.
| S-EPMC8409088 | biostudies-literature